OriGene Technologies Inc. is buying the life sciences business of SDIX (Nasdaq: SDIX), a biotechnology company.

SDIX, headquartered in Newark, Del., produces antigens and antibodies, which help the body to fight bacteria and viruses, for the pharmaceutical and biotechnology industries. Its life sciences technologies are used to research diseases and facilitate drug development. Terms of the deal were not disclosed.

Beijing-based OriGene develops, manufactures and sells genome research and diagnostic products. The company expects the deal to expand its antibody product capabilities.

In April, Covis Pharma Sarl bought the U.S. rights for five pharmaceutical products from Sanofi-Aventis U.S. LLC. 

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.